He Haiyang, Lipowska Malgorzata, Christoforou Anna Maria, Marzilli Luigi G, Taylor Andrew T
Department of Radiology, Emory University, Atlanta, GA 30322, USA.
Nucl Med Biol. 2007 Aug;34(6):709-16. doi: 10.1016/j.nucmedbio.2007.06.007.
The first human studies of a characterized radiopharmaceutical containing a {(99m)Tc(CO)(3)}(+) core, Na[(99m)Tc(CO)(3)(LAN)], demonstrated that Na[(99m)Tc(CO)(3)(LAN)] was an excellent renal imaging agent; however, its clearance was less than that of (131)I-orthoiodohippurate ((131)I-OIH), and it did not provide a direct measure of effective renal plasma flow. In order to develop a (99m)Tc renal agent with pharmacokinetic properties equivalent to those of (131)I-OIH, we investigated the (99m)Tc(CO)(3)/Re(CO)(3) complexes formed from carboxymethylmercaptosuccinic acid (CMSAH(3)) and thiodisuccinic acid (TDSAH(4)). Once the ligand is bound to (99m)Tc(CO)(3) through a thioether and two carboxyl groups, the complexes have at least one unbound carboxyl group, essential for the interaction with the renal tubular transporter.
X-ray crystal structural analysis of [NMe(4)][Re(CO)(3)(CMSAH)] was performed to interpret the nature of (99m)Tc tracers. CMSAH(3) and TDSAH(4) were radiolabeled by incubating each ligand and the precursor (99m)Tc(CO)(3)(H(2)O)(3) at 70 degrees C (pH 7) for 30 min. The products were purified by reversed-phase high-performance liquid chromatography, and biodistribution studies were performed in Sprague-Dawley rats, with (131)I-OIH as an internal control at 10 and 60 min.
Radiolabeling CMSAH(3) and TDSAH(4) with the (99m)Tc(CO)(3)(H(2)O)(3) precursor gave products quantitatively. Analysis of the Re(CO)(3) complexes with the CMSAH(3) and TDSAH(4) ligands demonstrates that ligands are bound in (99m)Tc/Re(CO)(3) complexes through a thioether and two deprotonated carboxyl groups (forming tridentate dianionic moieties, generally with two 5-membered chelate rings). Renal excretion at 60 min (activity in the urine as a percentage of (131)I-OIH) was 68+/-1% for Na(3)[(99m)Tc(CO)(3)(TDSA)] but was 98+/-1% for Na(2)[(99m)Tc(CO)(3)(CMSA)].
In rats, Na(2)[(99m)Tc(CO)(3)(CMSA)] is extracted by the kidneys and eliminated in the urine almost as rapidly as (131)I-OIH; consequently, Na(2)[(99m)Tc(CO)(3)(CMSA)] may provide a direct measure of effective renal plasma flow, and further evaluation in humans is warranted.
对含有{(99m)Tc(CO)(3)}(+)核心的一种特定放射性药物Na[(99m)Tc(CO)(3)(LAN)]的首批人体研究表明,Na[(99m)Tc(CO)(3)(LAN)]是一种出色的肾脏显像剂;然而,其清除率低于(131)I-邻碘马尿酸((131)I-OIH),且它无法直接测量有效肾血浆流量。为了研发一种药代动力学特性与(131)I-OIH相当的(99m)Tc肾脏药物,我们研究了由羧甲基巯基琥珀酸(CMSAH(3))和硫代琥珀酸(TDSAH(4))形成的(99m)Tc(CO)(3)/Re(CO)(3)配合物。一旦配体通过硫醚和两个羧基与(99m)Tc(CO)(3)结合,这些配合物就至少有一个未结合的羧基,这对于与肾小管转运体的相互作用至关重要。
对[NMe(4)][Re(CO)(3)(CMSAH)]进行X射线晶体结构分析以解释(99m)Tc示踪剂的性质。通过在70℃(pH 7)下将每种配体与前体(99m)Tc(CO)(3)(H(2)O)(3)孵育30分钟,对CMSAH(3)和TDSAH(4)进行放射性标记。产物通过反相高效液相色谱法纯化,并在Sprague-Dawley大鼠中进行生物分布研究,以(131)I-OIH作为10分钟和60分钟时的内部对照。
用(99m)Tc(CO)(3)(H(2)O)(3)前体对CMSAH(3)和TDSAH(4)进行放射性标记可定量得到产物。对含有CMSAH(3)和TDSAH(4)配体的Re(CO)(3)配合物的分析表明,配体通过硫醚和两个去质子化的羧基结合在(99m)Tc/Re(CO)(3)配合物中(形成三齿二阴离子部分,通常带有两个五元螯合环)。60分钟时的肾脏排泄(尿液中的活性占(131)I-OIH的百分比),对于Na(3)[(99m)Tc(CO)(开)(TDSA)]为68±1%,但对于Na(2)[(99m)Tc(CO)(3)(CMSA)]为98±1%。
在大鼠中,Na(2)[(99m)Tc(CO)(3)(CMSA)]被肾脏摄取并几乎与(131)I-OIH一样迅速地经尿液排出;因此,Na(2)[(99m)Tc(CO)(3)(CMSA)]可能提供有效肾血浆流量的直接测量值,值得在人体中进行进一步评估。